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Abstract 
Background: The l‑arabinose isomerase is an intracellular enzyme which converts l‑arabinose into l‑ribulose in living 
systems and d‑galactose into d‑tagatose in industrial processes and at industrial scales. d‑tagatose is a natural ketohex‑
ose with potential uses in pharmaceutical and food industries. The d‑galactose isomerization reaction is thermody‑
namically equilibrated, and leads to secondary subproducts at high pH. Therefore, an attractive l‑arabinose isomerase 
should be thermoactive and acidotolerant with high catalytic efficiency. While many reports focused on the set out 
of a low cost process for the industrial production of d‑tagatose, these procedures remain costly. When compared to 
intracellular enzymes, the production of extracellular ones constitutes an interesting strategy to increase the suitabil‑
ity of the biocatalysts.
Results: The l‑arabinose isomerase (l‑AI) from Lactobacillus sakei was expressed in Lactococcus lactis in fusion with 
the signal peptide of usp45 (SPUsp45). The l‑AI protein and activity were detected only in the supernatant of the 
induced cultures of the recombinant L. lactis demonstrating the secretion in the medium of the intracellular L. sakei 
l‑AI in an active form. Moreover, we showed an improvement in the enzyme secretion using either (1) L. lactis strains 
deficient for their two major proteases, ClpP and HtrA, or (2) an enhancer of protein secretion in L. lactis fused to the 
recombinant l‑AI with the SPUsp45. Th l‑AI enzyme secreted by the recombinant L. lactis strains or produced intracel‑
lularly in E. coli, showed the same functional properties than the native enzyme. Furthermore, when mice are fed with 
the L. lactis strain secreting the l‑AI and galactose, tagatose was produced in vivo and reduced the glycemia index.
Conclusions: We report for the first time the secretion of the intracellular l‑arabinose isomerase in the supernatant 
of food grade L. lactis cultures with hardly display other secreted proteins. The secreted l‑AI originated from the food 
grade L. sakei 23 K was active and showed the same catalytic and structural properties as the intracellular enzyme. The 
L. lactis strains secreting the l‑arabinose isomerase has the ability to produce d‑tagatose in vivo and conferred an anti‑
hyperglycemic effect to mice.
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Background
The l-arabinose isomerase (l-AI, EC 5.3.1.4) is an 
enzyme that mediates the conversion of l-arabinose to 
l-ribulose in vivo. At industrial scale this enzyme is used 
for the conversion of d-galactose into d-tagatose, thus 
it is also referred to as a d-galactose isomerase [1]. The 
d-tagatose is a d-fructose isomer currently used as a 
low calorie sweetener [2]. This ketohexose is a rare natu-
ral sugar tasting as sucrose and having similar physical 
properties [3] although it is not metabolized in humans 
and consequently has a very low caloric effect [4, 5]. In 
addition to its sweetener properties, d-tagatose is an 
anti-hyperglycemic factor and exhibits an efficient anti-
biofilm effect. Later, the d-tagatose was considered as a 
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GRAS “Generally Recognized as Safe” sweetener which 
can be used as a sugar substitute [6].
As previously reported, the isomerization of d-galactose 
into d-tagatose is thermodynamically equilibrated allow-
ing the shift of the reaction towards the tagatose produc-
tion when the temperature is increased [6, 7]. Thus, several 
thermoactive l-AIs have been isolated from thermophilic 
microorganisms including Thermotoga, Bacillus and Ther-
mus genera [8–10]. However when performed under alka-
line conditions, the isomerization has several drawbacks 
mainly the production of undesirable sub-products [6, 
11]. In order to improve the l-AIs suitability for biotech-
nological applications, many tools have been used such as: 
the screening of biodiversity to identify relevant enzymes 
with interesting properties, protein isolation, molecular 
modeling and rational design [12–14]. In this context, the 
thermoactivity, the metallic ions requirement and the cat-
alytic efficiency of several enzymes were probed [15, 16]. 
Recently, new production procedures of d-tagatose were 
described. We reported the concomitant bioconversion 
of d-galactose and d-glucose into d-tagatose and d-fruc-
tose, respectively. This original procedure was developed 
through the co-expression of a d-glucose isomerase and an 
l-arabinose isomerase in E. coli [17]. Another study [18] 
described the hydrolysis of lactose by the β-galactosidase 
from Pichia pastoris to galactose and glucose and the bio-
conversion of 30 % of d-galactose into d-tagatose with the 
addition of the l-AI from Arthrobacter sp. While several 
studies revealed that numerous efforts have been made 
to set out a low cost procedure for the industrial produc-
tion of tagatose, these processes remain costly [19]. This 
is mainly due to the biocatalyst production costs. Indeed, 
the l-AIs are intracellular enzymes that require not only 
the development of profitable procedures for their over-
expression but also for their extraction and purification. 
Compared to the intracellular enzymes, the production 
of extracellular biocatalysts is an attractive alternative to 
improve the industrial process profitability.
Although the proteins belonging to the isomerase fam-
ily are intracellular, in this study we report for the first 
time an efficient secretion in the extracellular medium 
of the l-AI from Lactobacillus sakei 23  K by the food 
grade bacterium Lactococcus lactis. We investigated the 
properties of the secreted protein and its efficacy to bio-
convert galactose into tagatose. We also investigated the 
functionality of the enzyme, the in vivo isomerization of 
galactose and the cognate anti-hyperglycemic effect of 
the produced tagatose in mice model.
Results and discussion
l‑AI secretion in L. lactis clpP‑htrA strain
l-AI is an intracellular protein, which is an efficient bio-
converter of galactose into tagatose. This latter property 
confers to this enzyme family a strong industrial inter-
est. However, the tagatose production remains to be 
improved mainly in terms of efficiency and process cost. 
Many efforts have been focused on the improvement of 
the biochemical properties of l-AI enzymes and their 
adaptation to industrial processes. However although 
the extraction and purification of the intracellular l-AIs 
increase the cost of production of these biocatalysts, the 
process steps have hardly been addressed. In this context, 
we investigated whether an intracellular l-AI could be 
produced in the extracellular medium. We choose L. lac-
tis as the heterologous host for the expression and secre-
tion test because (1) it is a food grade bacterium, (2) it 
secretes only one detectable extracellular protein (Usp45) 
[20], (3) it possesses only two major proteases, namely 
ClpP (intracellular) and HtrA (extracellular) (4) it has 
been used for the successful expression and secretion of 
several proteins of medical and industrial interest and for 
in situ delivery [21].
The gene encoding the l-AI from L. sakei 23  K was 
cloned under the control of pnis, the nisin-inducible pro-
moter, either directly or in fusion with the signal peptide 
originated from the L. lactis usp45 gene. Both construc-
tions as well as the empty vector were transformed in 
L. lactis NZ9000. The activity test showed that the l-AI 
activity is only found in the Nisin-induced cultures of 
recombinant L. lactis NZ9000 strain and its clpP-htrA 
derivative. No activity was observed in the strains har-
boring the empty plasmid. As expected, l-AI activity was 
clearly detected (21 ±  0.2 U/mg) in the cell fraction of 
L. lactis NZ9000 strain harboring the pCYT:araA plas-
mid, whereas no signal was detected in the supernatant 
(Table 1). Similar analysis of L. lactis NZ9000 strain har-
boring the pSEC:araA plasmid resulted in an l-AI activ-
ity of (10 ± 0.3 U/mg) in the supernatant fraction while 
not activity was detected in the cell fraction (Table  1). 
No activity was found in the cellular extracts from the 
cultures corresponding to the strains harbouring empty 
vectors. These results demonstrated for the first time that 
the L. sakei 23 K l-AI is expressed in an active form in 
L. lactis not only in its intracellular form but also as a 
secreted enzyme.
SDS-PAGE analysis of secreted l-AI revealed the 
presence of a protein band with an apparent molecu-
lar weight of about 56 kDa (Fig. 1a). Mass spectrometry 
experiments confirmed the identity of this band as the 
l-AI from L. sakei 23 K (data not shown). The ability to 
express the l-AI from L. sakei in L. lactis is in agreement 
with a recent report describing the expression of the Bifi-
dobacterium longum l-AI in L. lactis [18]. However to 
the best of our knowledge, there is so far no report on 
the secretion of the l-AI. This work constitutes not only 
the first report on the secretion of an l-AI, but also an 
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attractive way to produce this protein for biotechnologi-
cal applications.
To increase the l-AI secretion by L. lactis we used the 
pSEC:LEISS plasmid [22] which contains the usp45 sig-
nal peptide fused to 15 nucleotides that encodes to a 
9-residue synthetic propeptide, LEISSTCDA acting as an 
enhancer of protein secretion in L. lactis (Table  2). The 
l-AI activity was monitored in the supernatants of the 
L. lactis NZ9000 strains harboring the pSEC:araA and 
pSEC:LEISS:araA plasmids. The l-AI activities measured 
in the culture supernatants were 10 ± 0.3 and 13 ± 0.8 
U/mg for the strains carrying the pSEC:araA and the 
pSEC:LEISS:araA, respectively i.e. about half of the activ-
ity measured in the crude extract of NZ9000 carrying the 
pCYT:araA vector allowing the intracellular accumula-
tion of the enzyme.
It is well known that heterologous proteins can be tar-
geted by the proteases of the expressing host. We inves-
tigated the effect of the L. lactis proteases on the yield of 
l-AI production and secretion. Three isogenic mutants of 
the NZ9000 strain were used; they are deficient in each 
one or in both proteases of L. lactis; the intracellular pro-
tease ClpP and/or the extracellular cell surface protease 
HtrA (Table 2). As shown in Table 3, the measured activ-
ity for the clpP mutant, the htrA mutant and the clpP-
htrA double mutant were 17 ± 0.4, 19 ± 0.3 and 22 ± 0.6 
U/mg compared to 13 ± 0.8 U/mg obtained in the wild-
type NZ9000 strain carrying the same plasmid. These 
data indicate that each of the L. lactis proteases affects 
the yield of the secreted l-AI.
Altogether, the best production levels of the l-AI in L. 
lactis were obtained (1) in the pellet using the pCYT:araA 
(21 ± 0.2 U/mg) and (2) directly in the supernatant with 
the combination of the L. lactis clpP-htrA deficient 
strain with the pSEC:LEISS:araA expression plasmid 
(22 ± 0.3 U/mg).
Functional characterization of the secreted l‑AI
To study the biochemical properties of the secreted and 
the intracellular l-AI we purified this protein from L. 
lactis and E. coli, respectively. The analysis of the puri-
fied protein from E. coli and L. lactis by SDS-PAGE and 
gel filtration chromatography showed that both purified 
enzymes have a tetrameric arrangement (Fig.  1). These 
results evidenced that the secreted l-AI monomer has a 
functional tetrameric arrangement in the culture super-
natant. This observation is also supported by the fact that 
the secreted L. sakei l-AI and that all l-AIs reported so 
far, are active as homotetramers or homohexamers [7, 23].
Table 1 l-AI specific activity determination in  L. lactis 
NZ9000 harboring the secreted and  intracellular enzyme 
forms
ND not detected
Construction Specific activities (U/mg)
Supernatant Protein crude  
extract
NZ9000/pCYT:araA ND 21 ± 0.2
NZ9000/pSEC:araA 10 ± 0.3 ND
NZ9000/pSEC:LEISS:araA 13 ± 0.8 ND
































Fig. 1 a Coomassie brilliant blue‑stained gel, under reducing condi‑
tions. Lane 1 protein markers (molecular masses in kilodaltons); lane 
2, purified secreted l‑AI from MRS40; lane 3, purified l‑AI from E. coli. b 
Gel filtration chromatography profiles of the purified l‑AI prepara‑
tion issued from L. lactis (dashed line) and E. coli (continuous line). To 
determine the molecular weight of the purified l‑AI preparations we 
used protein markers of 669 (RT = 8.755 min), 440 (RT = 12.3 min), 
232 (RT = 14.02 min), 140 (RT = 16.7 min) and 66 kDa (RT = 20.9 min)
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To go one step further, we analyzed both purified pro-
tein fractions by circular dichroism. Our results revealed 
that the purified proteins from L. lactis (secreted form) 
and E. coli (intracellular form) exhibited similar confor-
mations (Fig. 2).
In addition, we studied the activity of the two purified 
protein preparations as function of the temperature and 
the pH. Both proteins fractions displayed the same opti-
mal temperature (30–40  °C) and optimal pH (5.0–7.0). 
The kinetic studies demonstrated that the purified l-
AI from L. lactis and E. coli had a catalytic efficiency of 
65 ± 0.8 and 64 ± 0.2/mM/min for l-arabinose, respec-
tively. These results established that the secreted protein 
not only have the same tetrameric arrangement as the 
protein over-expressed and purified from E. coli, but also 
the same biochemical and kinetic properties. This under-
lines again the efficiency of the secretion of this l-AI in 
L. lactis and the relevance of this mode of production for 
industrial applications. Such procedure constitutes an 
original promising tool for the secretion of this protein 
family in this food-grade host microorganism.
The secreted enzyme efficiently bioconverts d‑galactose 
into d‑tagatose
The ability of the MRS40 strain to bioconvert the d-galac-
tose into d-tagatose was studied. The induced cells are 
Table 2 Bacterial strains and plasmids used in this work
Strains Genotypes References
MRS36 Escherichia coli BL21 strain harboring the pMR36 plasmid [30]
NZ9000 MG1363 (nisRK genes in chromosome), plasmid free [33]
NZ9000 htrA NZ9000 defective for the htrA gene, plasmid free [29]
NZ9000 clpP NZ9000 defective for the clpP gene, plasmid free [34]
NZ9000 htrA clpP NZ9000 defective for the htrA and the clpP genes, plasmid free [35]
MRS37 NZ9000 harbouring the psec:LEISS:araA This work
MRS38 NZ9000 clpP harbouring the psec:LEISS:araA This work
MRS39 NZ9000 htrA harbouring the psec:LEISS:araA This work
MRS40 NZ9000 htrAclpP harbouring the psec:LEISS:araA This work
Plasmid Construct References
pMR36 Plasmid encoding the l‑arabinose isomerase encoding gene (araA) from L. sakei 23 K [30]
pCYT Vector derived from pGK12 carrying a chloramphenicol resistance gene and the pnis inducible promoter [22]
pSEC Vector derived from pGK12 carrying a chloramphenicol resistance gene and the pnis inducible promoter fused to the 
signal peptide of the usp45 gene
[22]
pSEC:LEISS Vector derived from pGK12 carrying a chloramphenicol resistance gene and the pnis inducible promoter in front of the 
signal peptide of usp45 fused to a sequence encoding the LEISTCDA polypeptide
[22]
pCYT:araA pCyt carrying the L. sakei araA gene under the control of the pnis promoter This work
pSEC:araA pSec carrying the L. sakei araA gene fused to the signal peptide of usp45and under the control of the pnis promoter This work
pSEC:LEISS:araA pSec:LEISS carrying under the control of the pnis promoter, the signal peptide of usp45 associated with the LEISSTCDA 
encoding fragment and fused to the L. sakei araA gene
This work
Table 3 Effect of the L. lactis mutant strains on the enzyme 
secretion efficiency
Strain Strain designation Specific activity (U/mg)
NZ9000 MRS37 13 ± 0.8
NZ9000 clpP MRS38 17 ± 0.4
NZ9000 htrA MRS39 19 ± 0.3
NZ9000 htrAclpP MRS40 22 ± 0.6
Fig. 2 Circular dichroism analysis of the pure l‑AI deriving from 
enzyme by MRS40 L. lactis strain (secreted form, in blue) and pro‑
duced in E. coli (intracellular form, in red)
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able to produce the d-tagatose from the d-galactose with 
a production rate of 32 % at pH 5.0, 6.0 and 7.0 (Fig. 3). In 
contrast in the same conditions, the non-induced MRS40 
cells did not produce detectable amount of d-tagatose 
and the galactose concentration remained stable (data 
not shown). The purified secreted l-AI displayed a high 
efficiency to isomerize the d-galactose into d-tagatose 
(Fig. 3). The analysis of the kinetic of d-galactose isomeri-
zation revealed that the bioconversion rates were higher 
with the purified enzyme (Fig.  3) than with the nisin-
induced MRS40 strain. In addition, the highest biocon-
version rate was achieved after 5 h in case of the purified 
enzyme and 7  h with the induced MRS40 cells (Fig.  3). 
It is likely to be related to a higher concentration of the 
purified enzyme compared to the amount of l-AI enzyme 
directly secreted by the induced bacterial culture.
As shown in Fig. 3, the conversion rates were not sig-
nificantly altered when the pH varied both in case of the 
induced MRS40 culture and of the purified enzyme. Such 
phenomenon may be explained by the wide range activity 
of the L. sakei l-AI [24].
These results highlighted the ability of the induced 
MRS40 cells and of the purified secreted l-AI to biocata-
lyze the d-tagatose production even at neutral and low 
pH. This underlines again the efficiency of the l-AI secre-
tion as a powerful system for the over-production of an 
active extracellular l-AI enzyme.
The produced d‑tagatose in vivo has an antihyperglycemic 
effect in mice
The use of tagatose in pharmaceutical applications has 
been previously reported. One of the main properties 
of this natural sugar is its anti-hyperglycemic effect [4]. 
To investigate this property, we studied the impact of 
the L. lactis strain secreting the l-AI and of the puri-
fied secreted enzyme on the glycemia of mice receiv-
ing d-galactose. This experimental procedure will also 
evidence the in  vivo activity of the l-AI and the abil-
ity of the L. lactis strain to actively synthesize the l-AI 
in  vivo. As illustrated in Fig.  4, the treatment of mice 
with d-galactose increased the glycemia values induced 
by glucose administration when compared to the results 
obtained with PBS only. On contrast, when the d-glucose 
administration was preceded by d-tagatose ingestion, 
the glycemia values did not increased (Fig. 4). These data 
highlighted the anti-hyperglycemic role of d-tagatose 
and confirmed what was previously reported regarding 
the glycemia protecting effect of this natural sugar [4, 25, 
26]. We then investigated the efficiency of the secreted 
l-AI to produce the d-tagatose in  vivo and to protect 
mice against a glycemia increase. As shown in Fig. 4, both 
non induced MRS40 and L. lactis clpP htrA/pSec:LEISS 
strain did not decreased the mice glycemia values after 
the administration of glucose. Moreover, the analysis of 
these glycemia profiles revealed that they were similar 
to that of the PBS control. The pretreatment of the mice 
with the nisin-induced MRS40 cells and d-galactose 
allowed a certain level of protection against the glyce-
mia increase in comparison to the mice treated with 
PBS and d-galactose. These data strongly suggests that 
Fig. 3 Bioconversion of the d‑galactose into d‑tagatose at different 
pH. The conversion was performed by either (1) the induced MRS40 
strain: pH 5 (open circle), pH 6 (open triangle), pH 7 (open square) or 
(2) the purified secreted l‑AI enzyme pH 5 (filled circle), pH 6 (filled 

















0                  20                 40                 60                 80                100
Time (min) 
(▲ ): PBS + D-Galactose
(○): PBS
(■): non- induced MRS40 + D-Galactose
(♦ ): L. lactis htrA-ClpP-/pSec:LEISS+D-Galactose
(□): Induced MRS40 + D-Galactose
(◊): Pure enzyme+ D-Galactose
(Δ): D-Tagatose
Fig. 4 Effect of tagatose on the glycemia in mice. Tests were carried 
out by administration of tagatose solution or through bioconversion 
of galactose in vivo using the pure secreted enzyme and the induced 
MRS40 strain. Filled triangle PBS + d‑galactose, filled square non‑
induced MRS40, filled diamond L. lactis htrA−ClpP−/pSec:LEISS, open 
circle PBS, open diamond pure enzyme +d‑galactose, open square 
induced MRS40, open triangle d‑tagatose
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the induced MRS40 strain secreted an active l-AI which 
was able to bioconvert in vivo the administered galactose 
into tagatose leading to the glycemia protection typical 
of this natural sugar. This interpretation is strongly sup-
ported by the fact that the mice treated with the puri-
fied l-AI enzyme and the d-galactose also showed a 
significant protection against the induced hyperglycemia 
(Fig.  4). The decrease of hyperglycemia was the highest 
after d-tagatose ingestion, intermediate with the inges-
tion of the purified enzyme and galactose and lower with 
the ingestion of the induced MRS40 strain and galactose. 
This observation is in agreement with (1) the elevated 
amount of d-tagatose used in this experiment (2  mg/
mice likely to be in excess), (2) the higher bioconversion 
activity reached with the purified enzyme compared to 
that obtained with the induced MRS40 culture as estab-
lished in our in vitro experiments (Fig. 3). Altogether our 
results revealed for the first time that the purified and 
secreted l-AIs convert in vivo the galactose into tagatose 
as shown by its protective effect against the hyperglyce-
mia observed in the animal model.
Conclusions
Here we report the secretion of the first l-AI from L. 
sakei 23  K, belonging to the isomerase family, in the 
food-grade L. lactis microorganism. The secreted l-AI 
from L. sakei 23  K displays the same biochemical and 
structural features when compared to the l-AI produced 
intracellularly in E. coli. Moreover, the L. lactis secreted 
l-AI efficiently bioconverted the d-galactose into d-taga-
tose in vivo displaying thus an anti-hyperglycemic effect 
in mice. In the near future we will focus our efforts on 
the study of the effect of tagatose concentration on the 
anti-hyperglycemic response. Furthermore, the optimi-
zation and/or isolation of new l-AI having high catalytic 
efficiency and stability will be of interest for the tagatose 
production at industrial scale. Such features stress the 
efficiency of the secretion of l-AI as a profitable way to 
produce active l-AI for industrial applications.
Methods
Bacterial strains, media, plasmids and growth conditions
The bacterial strains and plasmids used in this work 
are listed in Table  2. E. coli was grown in Luria–Ber-
tani medium at 37  °C [27]. L. lactis was grown in M17 
medium supplemented with 1  % glucose at 30  °C with-
out agitation. Plasmids were transformed in L. lactis by 
electroporation [28]. Plasmids were selected by using 
antibiotics: 5 µg of chloramphenicol per ml for L. lactis, 
10 µg of chloramphenicol per ml for E. coli, and 100 µg of 
ampicillin per ml for E. coli. Nisin was used at final con-
centration of 10 ng/ml for L. lactis. 1 mM of IPTG was 
used with E. coli.
PCR and DNA manipulation
Preparation of plasmid DNA was performed using the 
Miniprep kit (Promega). DNA digestion with restriction 
endonucleases and separation of fragments in agarose 
gel electrophoresis were performed as described by Sam-
brook et al. [27]. Polymerase chain reactions were carried 
out in a Gene Amp PCR System 9700 (Applied Biosys-
tems). The amplification reaction mixtures (100 µl) con-
tained Phusion High-Fidelity DNA polymerase buffer, 
10 pmol of each primer, 50 ng of DNA template, and 10 
units of High-Fidelity DNA polymerase (Fermentas). The 
cycling parameters were 94 °C for 5 min, followed by 35 
cycles at 94 °C for 30 s, 55 °C for 30 s and 72 °C for 90 s 
and finally 7  min at 72  °C. PCR products were purified 
using the GFX™ PCR DNA and Gel Band Purification Kit 
(Amersham Bioscience), following the manufacturer’s 
instructions.
l‑Arabinose isomerase molecular cloning strategy
The pMR36 plasmid was used as a template for the ampli-
fication of the gene encoding the l-AI from Lactobacillus 
sakei 23  K (Table  2). Two primers F-araA: AACTG 
CAGCATTAAATACAGAAAATTATGAATTTTGG and 
R-araA: GGACTAGTCCTTATTTAATATTGACGTAAG 
TCAAATC were used to amplify the araA gene flanked 
by the SpeI and PstI restriction sites. The resulting PCR 
fragment was purified and then digested with the latter 
restriction enzymes. The digested fragment was puri-
fied and subsequently ligated to the pCYT, pSEC and 
pSEC:LEISS vectors (to obtain pCYT:araA, pSEC:araA 
and pSEC:LEISS:araA, respectively) linearized with SpeI 
and NsiI restriction enzymes (Table 2). The ligation prod-
ucts were then transformed into either L. lactis NZ9000 
or L. lactis clpP-htrA strain [29]. Recombinant clones 
were analyzed by restriction and generated constructions 
were confirmed by DNA sequencing using an automated 
DNA sequencer (MWG Eurofins).
Preparation of crude extracts and protein purification
Recombinant L. lactis were grown until OD600 = 0.6 and 
induction with 10 ng/ml of nisin (Sigma) was performed 
during 3 h. The cells were harvested and the supernatant 
was concentrated using a 100  kDa cut-off membrane. 
The resulting protein fraction was subjected to an anion 
exchange chromatography (Mono-Q 5/50GL, GE Health-
care). Purification was achieved by a size exclusion chro-
matography step (S200 column, Amersham Bioscience) 
using an ÄKTA purifier system (Amersham Biosciences). 
The used buffer was 100  mM sodium acetate (pH 5.0) 
and elution fractions were 0.5 ml.
The harvested L. lactis cells were washed twice with 
100 mM sodium acetate buffer (pH 5.0) and disrupted by 
glass beads (diameter of 212–300 µm, v/v, Sigma). Crude 
Page 7 of 8Rhimi et al. Microb Cell Fact  (2015) 14:204 
cell extract were recovered by centrifugation (30,000×g, 
20 min at 4 °C).
Lactobacillus sakei l-AI produced in E. coli strain 
(MRS36) was over-expressed and purified as previously 
reported [30].
Protein quantification and electrophoresis
Protein concentrations were determined using the Brad-
ford method with bovine serum albumin as standard. The 
purified enzyme samples were migrated in 12 % sodium 
dodecyl sulfate–polyacrylamide gel electrophoresis 
(SDS-PAGE) according to the method of Laemmli [31]. 
Protein bands were visualized by Coomassie brilliant 
blue R-250 (BioRad) staining.
Enzyme assays
l-AI activity was established by determining the 
amount of generated l-ribulose or d-tagatose. Under 
standard conditions, the reaction mixture contained 
0.8  mM  Mg2+, 0.8  mM Mn2+, 50  μl of enzyme prepa-
ration at a suitable dilution; 5  mM of l-arabinose (or 
d-galactose) and sodium acetate buffer 100 mM (pH 5.0) 
to bring the final volume to 1  ml. The reaction mixture 
was incubated at 35 °C during 1 or 10 min for l-arabinose 
and d-galactose, respectively, followed by the incuba-
tion of the samples at 99 °C during 5 min. The generated 
l-ribulose (or d-tagatose) was measured by the cysteine 
carbazole sulfuric-acid method, and the absorbance was 
measured at 560 nm [32]. The d-tagatose production was 
also confirmed by high-pressure liquid chromatography 
(HPLC).
One unit of l-AI activity was defined as the amount of 
enzyme catalyzing the formation of 1  µmol keto-sugar 
per min under the above-specified conditions.
Circular dichroism experiments
Circular dichroism (CD) measurements were done with 
chirascan spectropolarimeter (Applied photophysics). 
Purified proteins were used at concentration of 1 mg/ml. 
The CD spectra of enzyme samples in a cuvette (0.1 cm) 
path length were analyzed in the far-UV region com-
prised between 200 and 280 nm. Scans were collected at 
0.1 nm intervals with a 1 nm bandwidth five times. Each 
spectrum was corrected by subtracting that of the solu-
tion containing the used buffer.
Biochemical and kinetic characterization
The effect of temperature on the activity was determined 
by incubating the purified enzyme at temperatures rang-
ing from 4 to 55 °C, whereas the pH profile was obtained 
by measuring the activity at various pH values from 3.0 
to 8.5 [3.0–5.0 with sodium acetate buffer, 6.0–7.0 with 
2-morpholinoethanesulfonic acid (MES) buffer and 7.5–
8.5 with Bicine buffer].
Kinetic properties were studied on the basis of 
Lineweaver–Burk plots. Assays were done in 100  mM 
sodium acetate buffer (pH 5.0), 0.8  mM  Mg2+, 0.8  mM 
Mn2+ and 1–800 mM substrate (l-arabinose or d-galac-
tose). Samples were incubated at 35  °C and the amount 
of keto-sugar generated (l-ribulose or d-tagatose) was 
determined by the cysteine-carbazole-sulfuric acid 
method [32].
In vitro d‑galactose bioconversion
Induced MRS40 cells and purified secreted l-AI with 
a final concentration of 109 CFU/ml and 0.3  mg/ml, 
respectively, were used to produce d-tagatose. Reac-
tions were carried out under different pH values (pH 5.0, 
6.0 and 7.0) by using 10 g/l d-galactose. d-tagatose was 
determined by cysteine carbazole method [32].
Animal experiments and glycemia measurement
Male C57BL/6 mice (6–8  weeks old) (Janvier, Le Gen-
est 428 Saint Isle, France or Taconic mice New York, 
USA) were maintained at the animal care facilities of the 
National Institute of Agricultural Research (IERP, INRA, 
Jouy-en-Josas, France) under specific pathogen-free con-
ditions. Mice were housed under standard conditions 
for a minimum of 1  week before experimentation. All 
experiments were performed in accordance with Euro-
pean Community rules and approved by the Animal Care 
Committee COMETHEA (Comité d’Ethique en Expéri-
mentation Animale du Centre INRA de Jouy-en-Josas et 
AgroParisTech, Jouy en Josas, France). Food intake was 
stopped 6 h before starting experiments.
L. lactis cellular pellets were harvested by centrifuga-
tion (3000g, at 4 °C) and washed three times with sterile 
PBS. The pellet was suspended in PBS to a final concen-
tration of 109 CFU. Groups of mice (n = 10) received a 
intragastric administration of either PBS, d-galactose 
(10 g/l), d-tagatose (10 g/l) or d-galactose (10 g/l) with: 
(1) MRS40 strain carrying the pSEC:LEISS vector, (2) 
induced MRS40 strain carrying the pSEC:LEISS:araA 
vector, (3) non-induced MRS40 strain carrying the 
pSEC:LEISS:araA vector and (4) the purified enzyme 
(0.3  mg/ml). The administered volume was 0.2  ml for 
each condition followed by a glucose challenge (1  g/kg 
body weight). Glycemia measurements were done by 
using the Accu-Chek performa system (Roche).
Statistical analysis
The data reported in this work were plotted using Sigma 
Plot (Version 9.0). Each value represents the mean for 
three independent experiments performed in duplicate.
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